No Data
No Data
Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target
Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $107
Cantor Fitzgerald analyst Pete Stavropoulos maintains $Vera Therapeutics(VERA.US)$ with a buy rating, and maintains the target price at $107.According to TipRanks data, the analyst has a success
Vera Therapeutics Director Sells Over $696k in Company Stock
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
Express News | Vera Therapeutics Inc - to Announce Origin 3 Trial Results in Q2 2025